Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.65 USD | -0.38% | -.--% | +11.81% |
Apr. 03 | Kinnate Biopharma Inc. Announces Board Resignations | CI |
Apr. 03 | Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index | CI |
Business Summary
Number of employees: 27
Managers
Managers | Title | Age | Since |
---|---|---|---|
Quah Cheng
CTO | Chief Tech/Sci/R&D Officer | - | - |
Richard Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-05-31 |
Priyanka Shah
IRC | Investor Relations Contact | - | - |
Barbara Warren
HRO | Human Resources Officer | - | 20-12-31 |
Jason Hampson
LAW | General Counsel | - | 21-06-06 |
David Madden
PRN | Corporate Officer/Principal | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 47,225,312 | 47,161,396 ( 99.86 %) | 0 | 99.86 % |
Company contact information
Kinnate Biopharma, Inc.
12830 El Camino Real Suite 150
92130, San Diego
+858-299-4699
http://www.kinnate.comSector
1st Jan change | Capi. | |
---|---|---|
+11.81% | 125M | |
+55.70% | 55.7B | |
+41.08% | 39.91B | |
-5.39% | 39.57B | |
-5.56% | 28.16B | |
+16.46% | 26.3B | |
-20.56% | 18.94B | |
+33.03% | 12.17B | |
+25.85% | 12.12B | |
+2.72% | 12.12B |
- Stock Market
- Equities
- KNTE Stock
- Company Kinnate Biopharma Inc.